Premium
Anti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD 6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia
Author(s) -
Schuster Friedhelm R.,
Meisel Roland,
Führer Monika,
Reuther Susanne,
Hauer Julia,
Tischer Johanna,
Feuchtinger Tobias,
Laws HansJürgen,
Kolb HansJochem,
Borkhardt Arndt
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12455
Subject(s) - medicine , peripheral blood stem cells , stem cell , refractory (planetary science) , bone marrow , transplantation , peripheral blood , surgery , gastroenterology , oncology , immunology , hematopoietic stem cell transplantation , biology , astrobiology , genetics
Summary The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD 6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.